

Suraj B Sable

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1648347/publications.pdf>

Version: 2024-02-01

20
papers

755
citations

516710

16
h-index

713466

21
g-index

21
all docs

21
docs citations

21
times ranked

1453
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberculosis Vaccine Development: Progress in Clinical Evaluation. <i>Clinical Microbiology Reviews</i> , 2019, 33, .	13.6	70
2	Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against <i>Mycobacterium tuberculosis</i> . <i>Scientific Reports</i> , 2016, 6, 25837.	3.3	16
3	Attrition of T-Cell Functions and Simultaneous Upregulation of Inhibitory Markers Correspond with the Waning of BCG-Induced Protection against Tuberculosis in Mice. <i>PLoS ONE</i> , 2014, 9, e113951.	2.5	36
4	O-mannosylation of the <i>Mycobacterium tuberculosis</i> Adhesin Apa Is Crucial for T Cell Antigenicity during Infection but Is Expendable for Protection. <i>PLoS Pathogens</i> , 2013, 9, e1003705.	4.7	30
5	Programmed Death 1 Lives Up to Its Reputation in Active Tuberculosis. <i>Journal of Infectious Diseases</i> , 2013, 208, 541-543.	4.0	8
6	Bacillus Calmette-Guérin vaccination using a microneedle patch. <i>Vaccine</i> , 2011, 29, 2626-2636.	3.8	85
7	<i>Mycobacterium tuberculosis</i> components stimulate production of the antimicrobial peptide hepcidin. <i>Tuberculosis</i> , 2011, 91, 314-321.	1.9	48
8	Cellular Immune Responses to Nine <i>Mycobacterium tuberculosis</i> Vaccine Candidates following Intranasal Vaccination. <i>PLoS ONE</i> , 2011, 6, e22718.	2.5	28
9	Nanobead-based interventions for the treatment and prevention of tuberculosis. <i>Nature Reviews Microbiology</i> , 2010, 8, 827-834.	28.6	127
10	Role of Hepcidin in the Innate Immune Response to <i>Mycobacterium tuberculosis</i> . <i>FASEB Journal</i> , 2008, 22, 556-556.	0.5	2
11	Tuberculosis subunit vaccine development: Impact of physicochemical properties of mycobacterial test antigens. <i>Vaccine</i> , 2007, 25, 1553-1566.	3.8	18
12	An in vitro model of the leukocyte interactions associated with granuloma formation in <i>Mycobacterium tuberculosis</i> infection. <i>Immunology and Cell Biology</i> , 2007, 85, 160-168.	2.3	57
13	Tuberculosis subunit vaccine design: The conflict of antigenicity and immunogenicity. <i>Clinical Immunology</i> , 2007, 122, 239-251.	3.2	37
14	Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice. <i>Clinical Immunology</i> , 2007, 125, 173-183.	3.2	26
15	Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins. <i>European Respiratory Journal</i> , 2006, 29, 337-346.	6.7	20
16	Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis. <i>FEMS Immunology and Medical Microbiology</i> , 2005, 45, 87-93.	2.7	48
17	Human immune recognition-based multicomponent subunit vaccines against tuberculosis. <i>European Respiratory Journal</i> , 2005, 25, 902-910.	6.7	19
18	Peripheral Blood and Pleural Fluid Mononuclear Cell Responses to Low-Molecular-Mass Secretory Polypeptides of <i>Mycobacterium tuberculosis</i> in Human Models of Immunity to Tuberculosis. <i>Infection and Immunity</i> , 2005, 73, 3547-3558.	2.2	32

#	ARTICLE	IF	CITATIONS
19	Multicomponent antituberculous subunit vaccine based on immunodominant antigens of <i>Mycobacterium tuberculosis</i> . <i>Vaccine</i> , 2005, 23, 4175-4184.	3.8	38
20	Immunodominance of low molecular weight secretory polypeptides of <i>Mycobacterium tuberculosis</i> to induce cytotoxic T-lymphocyte response. <i>Vaccine</i> , 2005, 23, 4947-4954.	3.8	9